Search Results
May 06, 2025, 20:00 ET Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema
efdamrofusp alfa (R&D code: IBI302), a recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein, for the treatment of diabetic macular edema (DME). This randomized, double-masked, multi-center, active-controlled Phase 2 clinical
More news about: Innovent Biologics
May 06, 2025, 09:00 ET IIHS AND CONSUMER REPORTS SELECT 14 SUBARU VEHICLES FOR TEEN DRIVERS
safer and healthier world. For 80 years, CR has provided evidence-based product testing and ratings, rigorous research, hard-hitting investigative journalism, public education and steadfast policy action on behalf of consumers' interests. For more information from CR, go to
More news about: Subaru of America, Inc.
May 06, 2025, 08:45 ET Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition,
More news about: Actinium Pharmaceuticals, Inc.
May 05, 2025, 20:00 ET 信達生物全球首創抗VEGF-補體雙靶融合蛋白
2025年5月6日 /美通社/ -- 信達生物製藥集團（香港聯交所股票代碼：01801），一家致力於研發、生產和銷售腫瘤、自身免疫、代謝及心血管、眼科等重大疾病領域創新藥物的生物製藥公司，在2025年視覺和眼科研究協會（ARVO）年會上以口頭報告的形式公布了其研發的重組人血管內皮生長因子受體（VEGFR）和人補體受體1（CR1）融合蛋白依莫芙普注射液（研發代號：IBI302）在新生血管性年齡相關性黃斑變性（nAMD）受試者中為期一年的臨床II期研究結果。ARVO 年會是全球最大的眼科與視覺研究盛會之一，上萬名眼科專家和臨床研究人員與會，旨在分享最新研究成果，並合作探索創新解決方案，本年度會議於5月4
More news about: 信達生物
May 05, 2025, 20:00 ET Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
of efdamrofusp alfa (R&D code: IBI302), a recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein, in Chinese subjects with neovascular age-related macular degeneration (nAMD) were presented orally at the 2025 Annual Meeting of the
More news about: Innovent Biologics
May 05, 2025, 08:22 ET Home First Finance Company announces robust Q4 and FY25 results - AUM grows 31.1% y-o-y
2,521 Cr vis-à-vis Rs 2,408 Cr as on Dec'24.FY25 Financial Performance: Total Income at Rs 1,539 Cr; growth of 33.1% y-o-y.PPOP stands at Rs 530 Cr; growth of
More news about: Home First Finance Company India Limited
May 05, 2025, 05:15 ET Fibe, CheQ collaborate to expand credit access and ensure responsible credit behaviour
been certified with ISO/IEC 27001 for its Information Security Management System (ISMS). Fibe has disbursed more than 7 million+ loans worth Rs. 26,000 Cr+ since inception through its lending partners. Winner of BW Festival of Fintech Lending Platform of the Year (Gold) and Fintech
More news about: Fibe
May 02, 2025, 10:07 ET Los vehículos Mazda aparecen en la lista de vehículos nuevos y usados recomendados para adolescentes de IIHS y CR
adolescentes del Insurance Institute for Highway Safety (IIHS, Instituto de Seguros para la Seguridad en las Carreteras) y del Consumer Reports (CR).
More news about: Mazda North American Operations
May 01, 2025, 14:47 ET Mazda Vehicles Named as IIHS and CR Recommended New and Used Vehicles for Teens
recommended new and used vehicles for teens from the Insurance Institute for Highway Safety (IIHS) and Consumer Reports (CR).
More news about: Mazda North American Operations
May 01, 2025, 11:00 ET Seed Coating Market worth $3.52 billion by 2030- Exclusive Report by MarketsandMarkets™
Canada), Chromatech Incorporated (US), Centor Group (Netherlands), Michelman, Inc. (US), Precision Labs (US), CR Minerals, LLC (US), and Universal Coating Systems (US). Get 10% Free Customization on this Report:
More news about: MarketsandMarkets
May 01, 2025, 03:19 ET IIT Hyderabad and Deakin University deepen partnership with launch of Advanced Manufacturing Research Innovation and Training (AMRIT)
and 5,300+ students (PG+PhD students accounting for about 60%), IITH has a strong research focus with ~4500 projects worth of Rs. 1400+ Cr of R&D funding (Rs. 335+ Cr in 2024-25), 11,500+ publications, 2,15,000+ citations, 500+ Patents (210 patents in 2024 and a commitment to "Patent a Day: Mission
More news about: Deakin University
Apr 30, 2025, 11:55 ET Eyewear Market to be worth $335.90 Billion by 2030 at CAGR 8.6% - Grand View Research, Inc.
Lens TypePolarized SunglassesNon-Polarized SunglassesLens MaterialCR-39PolycarbonatePolyurethaneOthersEyewear Market - Distribution Channel Outlook
More news about: Grand View Research, Inc.
Apr 30, 2025, 10:30 ET Global Times: Certainty of high-quality development can be observed from China's Q1 economic data
performance is supported by substantial strengths. Strength is evidenced by the products, market and data. The world's fastest high-speed rail CR450 stepped up its tests, the world's first 12,000-meter automated onshore drilling rig drilled 10,000 meters beneath the land, the world's first ultra-large
More news about: Global Times
Apr 30, 2025, 03:11 ET Genocury Biotech Announces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
Hematology Department at Tongji Hospital, a heavily pretreated relapsed/refractory (R/R) patient with advanced DLBCL achieved complete remission (CR) after 1 month of the in vivo CAR-T treatment, with durable response sustained over three months. Notably, the treatment eliminated
More news about: Genocury Biotech
Apr 29, 2025, 10:34 ET Barretos Motorcycles começa nesta quinta-feira com mais de 20 shows e atrações radicais
https://mma.prnewswire.com/media/2675862/Cr_dito_Mathias_Losonczi__2.jpg
More news about: Barretos Motorcycles
Apr 28, 2025, 09:16 ET Boehringer's new zongertinib data demonstrates durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
England Journal of MedicineData presented included an objective response rate (ORR) of 71%, with 7% of patients achieving complete responses (CR), and a 96% disease control rate (DCR)Previously unreported results, including median duration of response (DoR) of 14.1 months and median progression-free
More news about: Boehringer Ingelheim
Apr 28, 2025, 08:30 ET Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition,
More news about: Actinium Pharmaceuticals, Inc.
Apr 28, 2025, 08:00 ET Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition,
More news about: Actinium Pharmaceuticals, Inc.
Apr 26, 2025, 13:50 ET Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive,
More news about: Johnson & Johnson
Apr 25, 2025, 07:38 ET River EV Hits Two Major Milestones: INR 100 Cr Revenue & 1,000 Sales/Month
multimedia:https://www.prnewswire.com/in/news-releases/river-ev-hits-two-major-milestones-inr-100-cr-revenue--1-000-salesmonth-302438340.html
More news about: River
Apr 24, 2025, 09:55 ET CPSC Warns Consumers to Immediately Stop Using RiKiss Submersible LED Lights Due to Risk of Serious Injury or Death from Ingestion Hazard; Violations of Federal Regulations for Consumer Products with Coin Batteries; Sold on Amazon by RiKiss
LED Lights" followed by "Model: R3022." The product includes 10 color changing lights, a remote control, 20 preinstalled CR2032 lithium batteries in the lights and two preinstalled CR2032 lithium batteries in the remote control. These products were manufactured in China.
More news about: U.S. Consumer Product Safety Commission
Apr 24, 2025, 08:44 ET Peter England unveils its newest campaign 'The Gentlemen's League - League of Legends'
Birla Fashion and Retail Limited ABFRL is part of a leading Indian conglomerate, The Aditya Birla Group. With revenue of Rs. 13,996 Cr. spanning retail space of 11.9 million sq. ft. (as of March 31, 2024), it is India's first
More news about: Peter England
Apr 24, 2025, 02:23 ET Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
by Peter Nicklin, Chairman of the Board, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO and Renée Aguiar-Lucander. The call will include a review of the interim results and a business and pipeline update. It will be held in English.
More news about: Hansa Biopharma AB
Apr 24, 2025, 02:21 ET Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
by Peter Nicklin, Chairman of the Board, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO and Renée Aguiar-Lucander. The call will include a review of the interim results and a business and pipeline update. It will be held in English.
More news about: Hansa Biopharma AB
Apr 23, 2025, 00:30 ET Star Health Insurance Partners with Sunrisers Hyderabad as the Official Health Insurance Partner in T20
54000 crores. In FY24, Star Health reported a gross written premium of Rs 15,254 Cr and a net worth of Rs 6,339 Cr. For more information, visit
More news about: Star Health and Allied Insurance